Studies of mice rendered deficient in granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) have established unique roles for these cytokines in pulmonary homeostasis, resistance to infection, and antigen-specific T- and B-cell responses. In addition to these distinctive properties, however, GM-CSF and IL-3 also stimulate the development and activation of hematopoietic cells in many similar ways, raising the possibility that each factor might partially compensate for the other's absence in singly deficient mice. To test whether endogenous GM-CSF and IL-3 mediate redundant functions in vivo, we generated mice lacking both cytokines through sequential gene targeting experiments in embryonic stem (ES) cells. Surprisingly, doubly deficient animals, but not single knockouts, showed increased numbers of circulating eosinophils. Doubly deficient mice, moreover, developed weaker contact hypersensitivity reactions to haptens applied epicutaneously than mice deficient in either factor alone. Together, these findings delineate overlapping roles for GM-CSF and IL-3 in hematopoiesis and immunity.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) stimulate the proliferation, differentiation, and activation of hematopoietic cells in vitro in many similar ways.1 These overlapping functions reflect, at least in part, the shared use of the βc subunit for receptor signaling.2 The proximity of GM-CSF and IL-3 genomic sequences on mouse chromosome 11 and human chromosome 5 further underscores their close relationship and suggests that these cytokines may have evolved from an ancient gene duplication.3 

Notwithstanding these similarities, mice rendered singly deficient in GM-CSF or IL-3 manifest distinct phenotypes. Animals deficient in GM-CSF display normal steady-state hematopoiesis, but develop a lung disease resembling pulmonary alveolar proteinosis (PAP).4,5 The pathogenesis of PAP involves a reduction in surfactant clearance6 by defective alveolar macrophages.7,8 The βc knockout mice acquire comparable lung abnormalities9,10 due to closely related perturbations in surfactant metabolism11 and mount abrogated eosinophil responses as a consequence of the loss of βc-mediated interleukin-5 (IL-5) signaling.12,13Intriguingly, humans with PAP harbor high titers of neutralizing anti–GM-CSF antibodies14 or, less commonly, mutations in βc.15 GM-CSF–deficient mice also show compromised antigen-specific IgG and cytotoxic T-cell responses, interferon-γ (IFN-γ) production, and phagocyte function.16-19Together, these immune defects confer an increased susceptibility toListeria monocytogenes, group B streptococcus, andPneumocystis carinii,20-22 but partial protection against endotoxin challenge23 and collagen-induced arthritis.24 

Although IL-3–deficient mice similarly display intact steady-state hematopoiesis, unlike GM-CSF–deficient animals, they maintain normal pulmonary homeostasis.25 Mice deficient in IL-3 mount attenuated mast cell and basophil responses to parasite infection that result in compromised worm expulsion.26 They also show partial reductions in contact hypersensitivity reactions to haptens applied epicutaneously.25 Mice rendered deficient in βIL-3, a second signaling chain for this cytokine, develop blunted IL-3 responses, but show no perturbations of steady-state hematopoiesis.9 27 

Mice deficient in GM-CSF or IL-3 have been interbred with other hematopoietic growth factor knockouts to uncover possible redundancies of cytokine function in vivo.28 Mice lacking both GM-CSF and granulocyte colony-stimulating factor (G-CSF), unlike either single mutant, develop neutropenia early in life, resulting in increased mortality.29 Mice deficient in both GM-CSF and macrophage colony-stimulating factor (M-CSF) show more extensive pulmonary pathology and a higher incidence of fatal bacterial pneumonia than GM-CSF single knockouts.30 Mice deficient in both IL-3 and c-kit signaling display more severe defects in mast cell expansion and parasite resistance than either single knockout.26 On the other hand, mice lacking both IL-3 andmpl fail to develop further compromises in thrombopoiesis when compared with single mpl knockouts.31 

Because IL-3 signals through both βc and βIL-3, IL-3–deficient mice have been crossed with βc knockouts to generate mice with disrupted GM-CSF, IL-3, and IL-5 function.32 Although these animals mount reduced eosinophil responses due to the loss of IL-5 signaling and develop PAP due to the absence of GM-CSF signaling, no additional abnormalities have been described. In an effort to study more thoroughly the impact of dual GM-CSF and IL-3 ablation, without a concurrent loss in IL-5 signaling, we generated mice lacking both GM-CSF and IL-3 through sequential gene targeting experiments in embryonic stem (ES) cells. Surprisingly, doubly deficient animals have increased numbers of circulating eosinophils and are markedly compromised in contact hypersensitivity reactions.

Generation of GM-CSF/IL-3–deficient mice

Genomic sequences spanning the GM-CSF locus were excised from pPNT-GM-CSF and introduced into pPHT,33 a targeting vector designed for hygromycin and ganciclovir double selection. pPHT-GM-CSF was electroporated into an IL-3 heterozygous-deficient D3 ES cell clone selected for high germline transmission.25ES cells were propagated on G418/hygromycin resistant feeders (derived from C57Bl/6J-TgN[pPWL512hyg]1Ems JR2354 mice),34 and clones resistant to hygromycin, G418, and ganciclovir were characterized by Southern analysis. A full-length complementary DNA (cDNA) probe was used to analyze the IL-3 locus and the previously reported probe4 shown in Figure1 was used to analyze the GM-CSF locus. Targeted clones were injected into C57Bl/6 blastocysts to generate chimeras that transmitted the doubly mutant allele through the germline. Animals inheriting the targeted allele were interbred to obtain homozygous, doubly deficient animals. The mutant allele was then back-crossed 9 generations onto both C57Bl/6 and Balb/c backgrounds. The βc-deficient mice10 were similarly bred onto both C57Bl/6 and Balb/c backgrounds for a total of 9 generations. The βc-deficient mice were then crossed with GM-CSF/IL-3–deficient mice to obtain homozygous, triply deficient animals.

Fig. 1.

Generation of GM-CSF/IL3–deficient mice.

(A) Structure of the wild-type and targeted GM-CSF/IL-3 loci. (B). Genotyping of wild-type, heterozygous, and homozygous doubly deficient animals. Tail DNA was digested with either HindIII orBamHI and characterized by Southern analysis using the indicated probes.

Fig. 1.

Generation of GM-CSF/IL3–deficient mice.

(A) Structure of the wild-type and targeted GM-CSF/IL-3 loci. (B). Genotyping of wild-type, heterozygous, and homozygous doubly deficient animals. Tail DNA was digested with either HindIII orBamHI and characterized by Southern analysis using the indicated probes.

Close modal

Hematologicevaluation

Hematocrits, total and differential white blood cell and platelet counts, and bone marrow colony forming units-granulocyte, -macrophage, -granulocyte-macrophage, and -granulocyte, erythrocyte, macrophage, megakaryocyte (CFU-G, -M, -GM, and –GEMM, respectively) were determined as previously described.4 CFU-eosinophils (CFU-Eo) were determined in triplicate by culturing 7.5 × 105 bone marrow cells in MethoCult (StemCell Technologies, Vancouver, BC, Canada) supplemented with either 10 or 100 ng/mL recombinant IL-5. Bone marrow eosinophil numbers were determined on stained marrow sections using a micrometer and counting 300 cells along a linear millimeter in randomly chosen fields and on stained cytospins of bone marrow aspirates counting a total of 300 nucleated cells. For bone marrow transplantation experiments, 5 × 106 nucleated blood cells were harvested from donor femurs and injected into lethally irradiated (1100 rads in 2 doses) recipients. Peripheral blood counts were determined at days 9, 23, 64, and 100 after transplantation. GM-CSF, IL-3, and IL-5 were measured by enzyme-linked immunosorbent assay (ELISA) with the appropriate monoclonal antibodies (Endogen, Woburn, MA; Pharmingen, San Diego, CA).

Dendriticcells

Live B16-F10 melanoma cells (5 × 105) secreting murine flt3-ligand were injected subcutaneously into C57Bl/6 mutant and control animals to increase dendritic cell numbers, as previously described.35 Splenocytes and thymocytes were harvested 14 days later and stained with fluorescein isothiocyanate (FITC)- or phycoerythtin (PE)-conjugated monoclonal antibodies to CD11c, CD11b, I-Ab, CD8α, CD1d, CD3ε, CD4, NK1.1, B7-1, B7-2, and CD40 in the presence of blocking antibodies against FcγIII/II receptors (Pharmingen).

Contacthypersensitivity

Mice at least 7 weeks of age were sensitized epicutaneously on day 0 with 70 μL 4% 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone, Sigma, St Louis, MO) in acetone/olive oil (4:1) and challenged 5 days later on the ear with 20 μL 0.5% oxazolone or carrier only. To assess responsiveness to FITC (Sigma), mice were sensitized on day 0 with 400 μL 2.5% FITC in acetone/dibutyl phthalate (1:1) and challenged on day 6 with 40 μL 1.5% FITC. The hapten-specific increase in ear thickness at 24 hours was determined with a micrometer. Draining lymph nodes were harvested 24 to 48 hours after FITC application, processed to single cell suspension, and stained for major histocompatibility complex (MHC) II, B7-1, CD1d, and Ox40-ligand.36 For correction experiments, mice were injected intraperitoneally and subcutaneously with a total of 4700 ng GM-CSF and 810 ng IL-3, beginning 2 days before and finishing 2 days after sensitization (−48 hours, −24 hours, −18 hours, −4 hours, 0 hours, +4 hours, +18 hours, +24 hours, +48 hours). This regimen involved more intensive dosing than previously examined in studies of IL-3 singly deficient animals25 and was undertaken based on pilot experiments indicating an important dose-response effect. Cytokines were harvested from B16 cells engineered to secrete GM-CSF and IL-3.37 38 Control supernatants were from wild-type B16 cells.

Histology

Tissues were fixed in 10% neutral buffered formalin, processed routinely, and embedded in paraffin. They were then sectioned at 4 μm thickness and stained with hematoxylin and eosin. A semiquantitative scoring scheme for the intensity of contact hypersensitivity reactions was established as follows: trace, minimal edema, rare infiltrating lymphocytes or granulocytes, no epidermal changes; 1+, mild edema, focal infiltration of lymphocytes or neutrophils, no epidermal changes; 2+, easily visible edema, diffuse but scattered infiltration of lymphocytes, neutrophils, and eosinophils, foci of intraepidermal neutrophils; 3+, marked edema with numerous lymphocytes, many neutrophils and eosinophils, few intraepidermal abscesses; 4+, marked edema with numerous lymphocytes, neutrophils and eosinophils, many subcorneal and intraepidermal abscesses, focal keratinocyte necrosis.

Statistics

A one-way analysis of variance was used for statistical analysis. When significant differences were observed (P < .05), pairwise t tests were performed, using the Bonferroni correction for the multiple comparisons examined.

Generation of GM-CSF/IL-3–deficient mice

Because GM-CSF and IL-3 are separated by only 14 kb on chromosome 11,3 doubly deficient mice could not be obtained by interbreeding single knockout animals. Thus, mice lacking both cytokines were generated through sequential gene targeting experiments in ES cells. A hygromycin cassette replacing exons 3 and 4 of the GM-CSF locus was introduced by homologous recombination into IL-3 heterozygous deficient ES cells25 (Figure 1A). Two correctly targeted clones gave rise to germline transmission following injection into C57Bl/6 blastocysts. Genotyping of progeny mice revealed that GM-CSF and IL-3 were disrupted on the same allele (Figure 1B). Heterozygous mutant mice were interbred to generate homozygous GM-CSF/IL-3–deficient animals. Mutant mice were obtained at the expected frequencies, remained clinically healthy throughout 18 months of observation, and were fertile. Supernatants of concanavalin A-stimulated splenocytes from mutant animals showed no immune-reactive GM-CSF or IL-3 protein as determined by ELISA (not shown), confirming the generation of a null allele. The mutant allele was back-crossed 9 generations onto Balb/c and C57Bl/6 backgrounds for detailed analysis. Additional studies are required to delineate whether the modest decrease in fertility of GM-CSF–deficient animals29 39 is influenced by the simultaneous ablation of IL-3.

Pathology

Complete pathologic examination of GM-CSF/IL-3–deficient mice revealed abnormalities restricted to the lungs. A progressive accumulation of surfactant in the intra-alveolar spaces and an extensive lymphoid hyperplasia around both airways and veins was observed. Alveolar macrophages demonstrated a marked increase in intracellular surfactant. These features were similar to those previously found in GM-CSF–deficient mice,4 5 and morphologic analysis did not reveal an exacerbation by the concurrent loss of IL-3. Tissue hematopoietic populations and lymphoid organs failed to disclose additional alterations.

Hematopoiesis

The hematocrits and total circulating white blood cell and platelet counts were normal in GM-CSF/IL-3–deficient mice. Unexpectedly, examination of stained blood smears revealed that circulating eosinophils were increased in doubly deficient mice, as compared to single knockouts and wild-type controls (Table1). In contrast, circulating neutrophils, lymphocytes, and monocytes were not affected. Bone marrow-derived CFU-G, -M, -GM, and -GEMM were not altered in GM-CSF/IL-3–deficient animals, and bone marrow precursors did not show enhanced sensitivity to IL-5 in vitro (CFU-Eo in response to 10 ng IL-5 for +/+ mice: 15, 7, 15, 16.7; for −/− mice: 14, 6.3, 16.7, 13.7. Colony sizes were equivalent between +/+ and −/−mice). Enumeration of bone marrow eosinophils by examination of both fixed core sections and cytospins of marrow aspirates did not reveal differences between wild-type and doubly deficient animals (percent eosinophils for +/+ mice: 2.3, 1.3, 2, 1.3; for −/− mice: 1.7, 1.3, 1.3, 1.7). Although no IL-5 was consistently measurable in the blood (the sensitivity of ELISA was 25 pg/mL), interbreeding of GM-CSF/IL-3–deficient and βc-deficient mice resulted in abrogation of the eosinophilia (Table 1), strongly suggesting the participation of IL-5 in this response. Triply deficient mice also demonstrated an unexpected reduction in circulating lymphocytes.

To characterize hematopoiesis in GM-CSF/IL-3–deficient mice further, we lethally irradiated mutant animals and transplanted them with doubly deficient marrow. GM-CSF/IL-3–deficient mice achieved reconstitution that was comparable to wild-type controls, although there was a modest delay in the kinetics of leukocyte recovery (not shown), similar to that previously observed for GM-CSF–deficient animals.40 

Dendritic cell development

Recent studies have underscored the striking abilities of GM-CSF and IL-3 to stimulate the growth and differentiation of dendritic cells from hematopoietic precursors.41 However, we and others previously reported that mice deficient in GM-CSF or IL-3 maintained normal numbers of spleen and lymph node dendritic cells.4,25 42 Analysis of the spleens, thymi, and lymph nodes of GM-CSF/IL-3–deficient mice similarly revealed normal numbers of both myeloid- and lymphoid-type dendritic cells (not shown).

In an effort to identify other factors that might contribute to dendritic cell development in these animals, we implanted syngeneic tumor cells engineered to secrete high levels of flt3-ligand.35 These cells serve as an efficient vehicle for the systemic administration of flt3-ligand, a cytokine that dramatically augments dendritic cell numbers in wild-type mice.43 By 14 days after injection, there was a marked increase in splenocytes staining positive for CD11c and MHC II in both mutant and wild-type animals, with an average of 25% positive cells per spleen (Figure 2A,B). Because injection of flt3-ligand–expressing tumor cells produced a 3- to 4-fold increase in total spleen cellularity, a nearly 100-fold expansion of dendritic cell numbers was accomplished in the absence of GM-CSF and IL-3. Flt3-ligand–secreting tumor cells stimulated the generation of both myeloid-type (CD8α, CD11b+) and lymphoid-type (CD8α+, CD11b) dendritic cells (Figure 2C-F).43 44 No differences in B7-1, B7-2, CD40, or CD1d expression were observed between doubly deficient and wild-type animals (not shown). Taken together, these results suggest that flt3-ligand may be a critical regulator of dendritic cell development in vivo.

Fig. 2.

GM-CSF/IL-3–deficient and wild-type mice mount comparable dendritic cell responses to Flt3-ligand.

Splenocytes from mutant and wild-type animals were harvested 14 days after injection of Flt3-ligand–secreting B16 cells and stained for CD11c, MHC II, CD11b, and CD8. (A,C,E) Wild-type mice. (B,D,F) GM-CSF/IL-3–deficient mice.

Fig. 2.

GM-CSF/IL-3–deficient and wild-type mice mount comparable dendritic cell responses to Flt3-ligand.

Splenocytes from mutant and wild-type animals were harvested 14 days after injection of Flt3-ligand–secreting B16 cells and stained for CD11c, MHC II, CD11b, and CD8. (A,C,E) Wild-type mice. (B,D,F) GM-CSF/IL-3–deficient mice.

Close modal

Contact hypersensitivity

To evaluate dendritic cell function in GM-CSF/IL-3–deficient mice, we compared the abilities of mutant and wild-type animals to develop contact hypersensitivity reactions to epicutaneously applied haptens. Contact hypersensitivity is a form of delayed-type hypersensitivity in which hapten-protein conjugates are presented by cutaneous dendritic cells, following their migration to regional lymph nodes, to hapten-specific CD4+ and CD8+ T lymphocytes.45-48 On secondary hapten challenge, sensitized T cells initiate a local inflammatory response.

Although GM-CSF/IL-3–deficient mice were indistinguishable from wild-type littermates in the initial reaction to oxazolone challenge (data not shown), they exhibited a dramatically reduced response on secondary challenge, as measured by ear swelling (Figure3A). The degree of compromise was significantly greater than that previously reported for IL-3–deficient mice.25 Similar results were observed on both C57Bl/6 and Balb/c backgrounds and when FITC was used as the hapten (not shown).

Fig. 3.

Contact hypersensitivity reactions are compromised in GM-CSF/IL-3–deficient mice.

Mice were sensitized with oxazolone on the abdomen and foot pads on day 0 and challenged on the ear on day 5. Ear thickness was measured with a micrometer. (A) Wild-type versus IL-3–deficient,P < .0001. GM-CSF/IL-3 deficient versus IL-3 deficient,P < .0001. Similar results were observed in 8 independent experiments on both the C57Bl/6 and Balb/c backgrounds. (B) Defective contact hypersensitivity reactions can be reversed by the administration of GM-CSF and IL-3 protein during initial sensitization. Wild-type versus GM-CSF/IL-3 deficient, P < .0001. GM-CSF/IL-3 deficient versus control treatment, not significant. GM-CSF/IL-3 deficient versus GM-CSF/IL-3 treatment,P < .0001. Wild-type versus GM-CSF/IL-3 treatment, not significant. Similar results were observed in 5 independent experiments.

Fig. 3.

Contact hypersensitivity reactions are compromised in GM-CSF/IL-3–deficient mice.

Mice were sensitized with oxazolone on the abdomen and foot pads on day 0 and challenged on the ear on day 5. Ear thickness was measured with a micrometer. (A) Wild-type versus IL-3–deficient,P < .0001. GM-CSF/IL-3 deficient versus IL-3 deficient,P < .0001. Similar results were observed in 8 independent experiments on both the C57Bl/6 and Balb/c backgrounds. (B) Defective contact hypersensitivity reactions can be reversed by the administration of GM-CSF and IL-3 protein during initial sensitization. Wild-type versus GM-CSF/IL-3 deficient, P < .0001. GM-CSF/IL-3 deficient versus control treatment, not significant. GM-CSF/IL-3 deficient versus GM-CSF/IL-3 treatment,P < .0001. Wild-type versus GM-CSF/IL-3 treatment, not significant. Similar results were observed in 5 independent experiments.

Close modal

Although no pathologic differences between GM-CSF/IL-3–deficient and wild-type mice were noted in untreated skin or skin at the sensitization site, marked differences were apparent in skin at the challenge site (Figure 4A-C). In wild-type animals, the inflammatory response was characterized by an intense cellular infiltrate consisting primarily of neutrophils, lymphocytes, and eosinophils, which was associated with substantial dermal edema, hyperkeratosis, and focal intraepidermal abscesses (4+, see “Materials and methods” for description of semiquantitative scoring scheme). GM-CSF/IL-3–deficient animals, in contrast, generated a dramatically less intense cellular infiltrate with much less edema and little keratinocyte activation (trace to 1+). IL-3–deficient mice displayed intermediate reactions (2+) and GM-CSF–deficient animals developed strong reactions (3+), but these were reduced compared to wild-type controls (not shown).

Fig. 4.

Pathologic analysis of contact hypersensitivity.

Ears were harvested 24 hours after secondary oxazolone challenge. (A) Wild-type mouse, diluent only. (B) Sensitized wild-type mouse, hapten challenge. (C) Sensitized GM-CSF/IL-3–deficient mouse, hapten challenge. (D) Sensitized GM-CSF/IL-3–deficient mouse plus control treatment, hapten challenge. (E) Sensitized GM-CSF/IL-3-deficient mouse plus GM-CSF/IL-3 treatment, hapten challenge. All panels at ×200.

Fig. 4.

Pathologic analysis of contact hypersensitivity.

Ears were harvested 24 hours after secondary oxazolone challenge. (A) Wild-type mouse, diluent only. (B) Sensitized wild-type mouse, hapten challenge. (C) Sensitized GM-CSF/IL-3–deficient mouse, hapten challenge. (D) Sensitized GM-CSF/IL-3–deficient mouse plus control treatment, hapten challenge. (E) Sensitized GM-CSF/IL-3-deficient mouse plus GM-CSF/IL-3 treatment, hapten challenge. All panels at ×200.

Close modal

To delineate whether the compromise in contact hypersensitivity reflected a defect during the priming phase of the response, we injected doubly deficient mice with GM-CSF and IL-3 protein at the time of initial hapten application. Remarkably, the administration of these factors resulted in complete reconstitution of the attenuated secondary reaction, as measured both by ear swelling (Figure 3B) and pathologic analysis, where the intensity and character of the corrected response were indistinguishable from wild-type levels (Figure 4D,E). These findings formally establish a dual requirement for GM-CSF and IL-3 during hapten sensitization.

To explore this requirement further, we analyzed the dendritic cells that migrated to the draining lymph node following FITC application in doubly deficient and wild-type animals. Similar numbers of FITC-positive cells were found in both groups, and these cells showed comparable staining for CD11c, MHC II, B7-1, and CD1d (Ox40-ligand was not detected). Additional studies are required to identify which features of dendritic cells are compromised by the absence of GM-CSF and IL-3.

The generation of GM-CSF/IL-3–deficient mice has provided a system to test the hypothesis that these molecules mediate redundant functions in vivo. The experiments presented here definitively establish overlapping roles for these cytokines in both hematopoiesis and immunity.

Previous studies demonstrated that IL-3/βc-deficient mice have reduced numbers of circulating eosinophils, likely due to the abrogation of IL-5 signaling.32 It was thus surprising to find increased numbers of circulating eosinophils in GM-CSF/IL-3–deficient animals. IL-5 likely contributed to this eosinophilia, however, because mice lacking GM-CSF, IL-3, and βc showed decreased numbers of eosinophils. The mechanism underlying the eosinophilia is currently unclear. The numbers of mature eosinophils and their progenitors were not increased in the bone marrow of GM-CSF/IL-3–deficient mice, suggesting that the steady-state production of this lineage is probably not altered. It is possible that the egress of eosinophils from the circulation is compromised, and future investigations aimed at quantifying eosinophil numbers in a variety of tissue populations will help clarify this idea further. A prolongation of eosinophil life span is an additional consideration that needs to be explored. In either case, it is tempting to speculate that IL-5 normally competes with GM-CSF and IL-3 in signaling through βc.

Because recent investigations have highlighted the abilities of GM-CSF and IL-3 to stimulate dendritic cell development,41 we quantified these cells in the spleen, thymus, and lymph nodes of GM-CSF/IL-3–deficient animals. However, as in our previous studies of mice singly deficient in GM-CSF4 or IL-3,25dendritic cell numbers were not altered in the doubly mutant mice. These results suggest that GM-CSF and IL-3 are either not involved in steady-state dendritic cell development or are components of a larger network of redundant cytokines. In this context, flt3-ligand is likely to play a decisive role, based on its ability to increase dendritic cells in GM-CSF/IL-3–deficient mice by nearly 2 logs. Indeed, a recent report of flt3-ligand knockout mice demonstrated a substantial reduction of dendritic cell numbers in the spleen, thymus, and lymph nodes.49 

Although GM-CSF/IL-3–deficient mice maintained normal dendritic cell numbers, these animals were markedly compromised in priming contact hypersensitivity reactions. The degree of impairment significantly exceeded that observed in GM-CSF or IL-3 single knockouts, establishing a dual requirement for both cytokines in this response. Although the administration of GM-CSF and IL-3 protein at the time of hapten sensitization reversed the defect, we have not yet identified the specific pathway compromised in GM-CSF/IL-3–deficient mice. Unlike CCR7 knockout mice,50 which fail to mount contact hypersensitivity reactions due to the lack of dendritic cell migration from the skin to the draining lymph nodes, GM-CSF/IL-3–deficient animals display normal numbers of hapten-loaded dendritic cells in the draining nodes. Moreover, although B7 family members51,52and Ox40-ligand36 also contribute to hapten-specific priming, we were unable to detect differences in these molecules between doubly deficient animals and wild-type controls. Additional experiments are required to elucidate the mechanisms underlying defective hapten sensitization in the absence of GM-CSF and IL-3.

Our own studies have revealed that vaccination with irradiated tumor cells engineered to secrete GM-CSF and, to a lesser extent IL-3, stimulate potent, specific, and long-lasting antitumor immunity.37,38,53 Although we have not yet examined the susceptibility of GM-CSF/IL-3–deficient mice to tumor induction, recent investigations have established a striking inverse correlation between the ability to generate contact hypersensitivity reactions to polycyclic hydrocarbons and susceptibility to the carcinogenic effects of these agents.54 These results raise the intriguing possibility that GM-CSF and IL-3 may, like IFN-γ,55contribute to cancer immunosurveillance.

We thank Glenn Begley (WAIMR) and Lorraine Robb (WEHI) for providing βc-deficient mice and Andy Chen and Arlene Sharpe (Brigham and Womens' Hospital) for providing antibodies against OX40-ligand. We thank Christine Sheehan and Esther Brisson (Albany Medical College) for excellent help with the histologic specimens, Susan Lazo-Kallanian and John Daley for excellent help with the fluorescence-activated cell sorting studies, Patricia Bernardo for excellent help with the statistics, Kurt Edelman for excellent technical help, and the staff of the Redstone Animal Facility for excellent help with maintenance of the mouse colony. We thank Jim Griffin for critical review of the manuscript.

Supported by the Swiss National Science Foundation (N.M., S.G.), the Swiss Cancer League (S.G.), the Cancer Research Institute/Partridge Foundation, and CA74886 (G.D.). G.D. is a Clinical Scholar of the Leukemia and Lymphoma Society. S.G. and N.M. should be considered equal first authors.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Metcalf
D
Hemopoietic regulators: redundancy or subtlety?
Blood.
82
1993
3515
3523
2
Gorman
D
Itoh
N
Jenkins
N
et al
Chromosomal localization and organization of the murine genes encoding the β subunits (AIC2A and AIC2B) of the interleukin 3, granulocyte/macrophage colony-stimulating factor and interleukin 5 receptors.
J Biol Chem.
267
1992
15842
15848
3
Lee
JS
Young
IG
Fine-structure mapping of the murine IL-3 and GM-CSF genes by pulsed-field gel electrophoresis and molecular cloning.
Genomics.
5
1989
359
362
4
Dranoff
G
Crawford
AD
Sadelain
M
et al
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
Science.
264
1994
713
716
5
Stanley
E
Lieschke
GJ
Grail
D
et al
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.
Proc Natl Acad Sci U S A.
91
1994
5592
5596
6
Ikegami
M
Ueda
T
Hull
W
et al
Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation.
Am J Physiol.
14
1996
L650
658
7
Huffman
JA
Hull
WM
Dranoff
G
Mulligan
RC
Whitsett
JA
Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice.
J Clin Invest.
97
1996
649
655
8
Nishinakamura
R
Wiler
R
Dirksen
U
et al
The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 βc receptor-deficient mice is reversed by bone marrow transplantation.
J Exp Med.
183
1996
2657
2662
9
Nishinakamura
R
Nakayama
N
Hirabayashi
Y
et al
Mice deficient for the IL-3/GM-CSF/IL-5 βc receptor exhibit lung pathology and impaired immune response, while βIL-3 receptor-deficient mice are normal.
Immunity.
2
1995
211
222
10
Robb
L
Drinkwater
CC
Metcalf
D
et al
Hematopoietic and lung abnormalities in mice with a null mutation of the common β subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5.
Proc Natl Acad Sci U S A.
92
1995
9565
9569
11
Reed
J
Ikegami
M
Robb
L
et al
Distinct changes in pulmonary surfactant homeostasis in common β-chain- and GM-CSF-deficient mice.
Am J Physiol Lung Cell Mol Physiol.
278
2000
L1164
L1171
12
Yoshida
T
Ikuta
K
Sugaya
H
et al
Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5Rα-deficient mice.
Immunity.
4
1996
483
494
13
Kopf
M
Brombacher
F
Hodgkin
PD
et al
IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.
Immunity.
4
1996
15
24
14
Kitamura
T
Tanaka
N
Watanabe
J
et al
Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.
J Exp Med.
190
1999
875
880
15
Dirksen
U
Nishinakamura
R
Groneck
P
et al
Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common β chain expression.
J Clin Invest.
100
1997
2211
2217
16
Wada
H
Noguchi
Y
Marino
M
Dunn
A
Old
L
T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice.
Proc Natl Acad Sci U S A.
94
1997
12557
12561
17
Noguchi
Y
Wada
H
Marino
M
Old
L
Regulation of IFN-γ production in granulocyte-macrophage colony-stimulating factor-deficient mice.
Eur J Immunol.
28
1998
3980
3988
18
Scott
C
Hughes
D
Cary
D
et al
Functional analysis of mature hematopoietic cells from mice lacking the βc chain of the granulocyte-macrophage colony-stimulating factor receptor.
Blood.
92
1998
4119
4127
19
Zhan
Y
Basu
S
Lieschke
G
et al
Functional deficiencies of peritoneal cells from gene-targeted mice lacking G-CSF or GM-CSF.
J Leukocyte Biol.
65
1999
256
264
20
Zhan
Y
Lieschke
G
Grail
D
Dunn
A
Cheers
C
Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice.
Blood.
91
1998
863
869
21
LeVine
A
Reed
J
Kurak
K
Cianciolo
E
Whitsett
J
GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection.
J Clin Invest.
103
1999
563
569
22
Paine
RI
Preston
A
Wilcoxen
S
et al
Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice.
J Immunol.
164
2000
2602
2609
23
Basu
S
Dunn
A
Marino
M
et al
Increased tolerance to endotoxin by granulocyte-macrophage colony-stimulating factor-deficient mice.
J Immunol.
159
1997
1412
1417
24
Campbell
I
Rich
M
Bischof
R
et al
Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice.
J Immunol.
161
1998
3639
3644
25
Mach
N
Lantz
C
Galli
S
et al
Involvement of interleukin-3 in delayed-type hypersensitivity.
Blood.
91
1998
778
783
26
Lantz
C
Boesiger
J
Song
C
et al
Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites.
Nature.
392
1998
90
93
27
Nicola
NA
Robb
L
Metcalf
D
et al
Functional inactivation in mice of the gene for the interleukin-3 (IL-3)-specific receptor β-chain: implications for IL-3 function and the mechanism of receptor transmodulation in hematopoietic cells.
Blood.
87
1996
2665
2674
28
Arai
K-I
Lee
F
Miyajima
A
et al
Cytokines: coordinators of immune and inflammatory responses.
Annu Rev Biochem.
59
1990
783
836
29
Seymour
J
Lieshhke
G
Grail
D
et al
Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival.
Blood.
90
1997
3037
3049
30
Lieschke
GJ
Stanley
E
Grail
D
et al
Mice lacking both macrophage- and granulocyte-macrophage colony-stimulating factor have macrophages and coexistent osteopetrosis and severe lung disease.
Blood.
84
1994
27
35
31
Gainsford
T
Roberts
A
Kimura
S
et al
Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production.
Blood.
91
1998
2745
2752
32
Nishinakamura
R
Miyajima
A
Mee
P
Tybulewicz
V
Murray
R
Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions.
Blood.
88
1996
2458
2464
33
Williams
B
Schmitt
E
Remington
L
et al
Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences.
EMBO J.
13
1994
4251
4259
34
Johnson
K
Lerner
C
Di Lacio
L
et al
Transgenic mice for the preparation of hygromycin-resistant primary embryonic fibroblast feeder layers for embryonic stem cell selections.
Nucleic Acids Res.
23
1995
1273
1275
35
Mach
N
Gillessen
S
Wilson
SB
et al
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand.
Cancer Res.
60
2000
3239
3246
36
Chen
A
McAdam
A
Buhlmann
J
et al
Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.
Immunity.
11
1999
689
698
37
Dranoff
G
Jaffee
E
Lazenby
A
et al
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Proc Natl Acad Sci U S A.
90
1993
3539
3543
38
Sampson
J
Archer
G
Ashley
D
et al
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system.
Proc Natl Acad Sci U S A.
93
1996
10399
10404
39
Robertson
S
Roberts
C
Farr
K
Dunn
A
Seamark
R
Fertility impairment in granulocyte-macrophage colony-stimulating factor-deficient mice.
Biol Reprod.
60
1999
251
261
40
Dranoff
G
Mulligan
RC
Activities of granulocyte-macrophage colony stimulating factor revealed by gene transfer and gene knockout studies.
Stem Cells.
12(suppl 1)
1994
173
184
41
Cella
M
Sallusto
F
Lanzavecchia
A
Origin, maturation, and antigen presenting function of dendritic cells.
Curr Opin Immunol.
9
1997
10
16
42
Vremec
D
Lieschke
G
Dunn
A
et al
The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs.
Eur J Immunol.
27
1997
40
44
43
Maraskovsky
E
Brasel
K
Teepe
M
et al
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.
J Exp Med.
184
1996
1953
1961
44
Pulendran
B
Lingappa
J
Kennedy
M
et al
Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice.
J Immunol.
159
1997
2222
2231
45
Eisen
HN
Orris
L
Belman
S
Elicitation of delayed allergic skin reactions with haptens: the dependence of elicitation on hapten combination with protein.
J Exp Med.
95
1952
473
487
46
Silberberg
I
Baer
RL
Rosenthal
SA
The role of Langerhans cells in allergic contact hypersensitivity: a review of findings in man and guinea pigs.
J Invest Dermatol.
66
1976
210
217
47
Bacci
S
Alard
P
Dai
R
Nakamura
T
Streilein
J
High and low doses of haptens dictate whether dermal or epidermal antigen-presenting cells promote contact hypersensitivity.
Eur J Immunol.
27
1997
442
448
48
Gocinski
BL
Tigelaar
RE
Roles of CD4+ and CD8+ T cells in murine contact sensitivity revealed by in vivo monoclonal antibody depletion.
J Immunol.
144
1990
4121
4128
49
McKenna
H
Stocking
K
Miller
R
et al
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells.
Blood.
95
2000
3489
3497
50
Forster
R
Schubel
A
Breitfeld
D
et al
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.
Cell.
99
1999
23
33
51
Rauschmayr-Kopp
T
Williams
I
Borriello
F
Sharpe
A
Kupper
T
Distinct roles for B7 costimulation in contact hypersensitivity and humoral immune responses to epicutaneous antigen.
Eur J Immunol.
28
1998
4221
4227
52
Tang
A
Judge
T
Nickoloff
B
Turka
L
Suppression of murine allergic contact dermatitis by CTLA4Ig: tolerance induction of Th2 responses requires additional blockade of CD40-ligand.
J Immunol.
157
1996
117
125
53
Soiffer
R
Lynch
T
Mihm
M
et al
Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma.
Proc Natl Acad Sci U S A.
95
1998
13141
13146
54
Elmets
C
Athar
M
Tubesing
K
et al
Susceptibility to the biological effects of polyaromatic hydrocarbons is influenced by genes of the major histocompatibility complex.
Proc Natl Acad Sci U S A.
95
1998
14915
14919
55
Kaplan
D
Shankaran
V
Dighe
A
et al
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice.
Proc Natl Acad Sci U S A.
95
1998
7556
7561

Author notes

Glenn Dranoff, Dana-Farber Cancer Institute, Dana 510E, 44 Binney St, Boston, MA 02115; e-mail:glenn_dranoff@dfci.harvard.edu.

Sign in via your Institution